Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis

  • PDF / 1,540,977 Bytes
  • 13 Pages / 595.276 x 790.866 pts Page_size
  • 5 Downloads / 203 Views

DOWNLOAD

REPORT


ORIGINAL COMMUNICATION

Dimethyl fumarate vs Teriflunomide: an Italian time‑to‑event data analysis Emanuele D’Amico1   · Aurora Zanghì1 · Mariangela Sciandra2 · Roberta Lanzillo3 · Graziella Callari4 · Antonio Cortese5 · Giacomo Lus6 · Matteo Lucchini7 · Maria Buccafusca8 · Simona Bonavita9 · Antonio Gallo10 · Erica Curti11 · Alberto Gajofatto12 · Elisabetta Signoriello6 · Alvino Bisecco10 · Francesca Gobbin12 · Maria Teresa Ferrò13 · Gina Ferrazzano14 · Maddalena Sparaco9 · Paola Valentino15 · Massimiliano Mirabella7 · Franco Granella11 · Vincenzo Bresciamorra3 · Luigi Maria Edoardo Grimaldi4 · Francesco Patti1 on behalf of ITALIANDIME-TERI group Received: 20 February 2020 / Revised: 23 May 2020 / Accepted: 28 May 2020 © Springer-Verlag GmbH Germany, part of Springer Nature 2020

Abstract Background  The introduction of oral disease-modifying therapies (DMTs) for relapsing–remitting multiple sclerosis (RRMS) changed algorithms of RRMS treatment. Objectives  To compare the effectiveness of treatment with dimethyl fumarate (DMF) and teriflunomide (TRF) in a large multicentre Italian cohort of RRMS patients. Materials and Methods  Patients with RRMS who received treatment with DMF and TRF between January 1st, 2012 and December 31st, 2018 from twelve MS centers were identified. The events investigated were “time-to-first-relapse”, “timeto-Magnetic-Resonance-Imaging (MRI)-activity” and “time-to-disability-progression”. Results  1445 patients were enrolled (1039 on DMF, 406 on TRF) and followed for a median of 34 months. Patients on TRF were older (43.5 ± 8.6 vs 38.8 ± 9.2 years), with a predominance of men and higher level of disability (p